Pharmaceutical compositions with hydrating and lubricating activity

ABSTRACT

The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vaginal dryness and/or atrophic vaginitis; said compositions can also be used successfully to lubricate the genital mucosa.

FIELD OF THE INVENTION

The present invention discloses pharmaceutical compositions comprisingester derivatives of hyaluronic acid for use as a topical treatment indisorders of the vaginal mucosa characterised by loss of elasticity andhydration, such as vaginal dryness and/or atrophic vaginitis, and aslubricants for the genital mucosa.

BACKGROUND OF THE INVENTION

The vaginal mucosa is the surface of the vagina facing the lumen. Itconsists of a thick multi-layered lining epithelium without keratin butprotected by mucus, which is rich in mucopolysaccharides secreted bymuciparous cells. The cells of the vaginal mucosa, especially those ofthe outermost layers, are hormone-correlated, and play an important partin maintaining the metabolic balance of the vaginal environment. Saidcells are therefore stimulated by oestrogens to synthesise and storelarge quantities of glycogen (sugar reserve), which is introduced intothe vaginal lumen when said cells are shed. The glycogen released ismetabolised by the bacterial flora normally present in the vagina, withthe formation of lactic acid responsible for the acid local pH,especially towards the middle of the menstrual cycle. Lactobacilli forma biofilm that coats the vaginal mucosa and, together with the low pH,protects the environment against aggression by pathogenic andopportunistic micro-organisms and against excessive growth of bacteriawhich are innocuous in themselves, and normally present in small amountsin the vagina as normal “resident” microbial flora.

The innermost layer of the mucosa, the lamina propria, consists offibroelastic connective tissue, and its deepest parts are richlyvascularised. Although the vaginal mucosa does not contain glands,stimulation, arousal and sexual intercourse increase the secretion,which serves to lubricate its surface. This secretion actuallyoriginates from the glands of the cervix, together with the transudateoriginating from the lamina propria.

It will easily be deduced from this complex picture that any variationin the vaginal equilibrium leads to alterations of the mucosa, whichtends to lose its hydration and turgidity, giving rise to vaginaldryness. The hydration and lubrication, thickness, structure andfunctionality of the vulvovaginal mucosa change from birth to menopause,throughout the woman's fertile life, but the major changes take placeduring and after the menopause, when oestrogen stimulation isdrastically reduced. Other causes of vaginal dryness are the post-partumperiod, lactation, chronic use of some drugs (such as antitumorals,antidepressants and antihistamines), surgical operations (removal of theovaries) and concomitant disorders such as obesity or diabetes. Thereare also mental and physical causes such as stress, particularlyrestrictive diets, intense physical activity, and serious socialproblems.

Finally, dryness can be caused by mental or relationship problems thatprevent regular mucus production during the stages of sexual arousal.

Vaginal dryness, regardless of cause, affects about 50% of women, and ismanifested by a sensation of dryness, vaginal itching, discomfort, painduring sexual intercourse and, in the more obstinate forms, inflammationand urinary problems. The altered trophism of the vaginal mucosa pavesthe way for opportunistic fungal or bacterial infections; in thesesituations, the disorder is more specifically called vaginal atrophy oratrophic vaginitis.

The treatment of vaginal dryness and atrophic vaginitis, apart frompharmacological treatment of the bacterial or fungal infection orhormone replacement treatment (which is not always applicable), ismainly comprising the use of lubricants with a soothing and emollientaction, characterised by the carrier of which they are composed.Lubricants may be:

oil-based: generally polymer gels derived from petroleum. They have along-lasting effect, because they do not dry on contact with air and donot interact unfavourably with bodily fluids, but are not very lubricant(they produce friction) and above all dissolve latex, which means thatthey cannot be used with a condom, as they would reduce itscontraceptive efficacy and its efficacy against sexually transmitteddiseases;

silicone-based: the latest generation, which resemble hydrogels. Theyare easily spread and dry slowly, but can attack silicone-basedproducts;

water-based: gels with a high water content which are easily spreadable,compatible with biological fluids and have no effect on the latex ofwhich condoms are made; however, although they give an excellentsensation of well-being after application, they dry very easily, andconsequently require frequent application.

Water-based products are certainly the most widely used when not onlyextempore lubrication, but also a long-lasting lubricating, emollient,protective effect, is required.

One of the ingredients most widely used in these preparations ishyaluronic acid (HA), a polymer ubiquitously present in the human bodywhich possesses multiple properties; in particular, for topicalapplication it acts as a hydrating, emollient, mucoadhesive, healing andtissue-regenerating agent. It absorbs a great deal of water (up to 1000times its own weight) and gives rise to water-soluble gels which areeasily spread and comfortable to apply. However, the high water contentcauses them to dry quite quickly.

It has now surprisingly been found that some hyaluronic acidderivatives, obtained by esterification of HA, can be used successfullyin these applications, overcoming all the problems existing in the stateof the art.

Some HA ester derivatives have already been successfully used in otherfields, such as tissue engineering; as described in EP618817, forexample, 75 or 100% derivatives can be reduced to fibres which, whenprocessed in the form of non-woven fabrics, constitute athree-dimensional matrix usable in the dermatological field.

The pharmaceutical compositions of the invention consist of hyaluronicacid ester with benzyl alcohol, wherein 50% of the carboxyl groups ofhyaluronic acid are esterified with the corresponding hydroxyl groups ofbenzyl alcohol (Hyaff11p50); the ester thus obtained absorbs less waterthan HA “as is”, is less water-soluble and more compact but,surprisingly, also performs a more effective, longer-lastingmoisturising effect than known preparations containing HA sodium salt.

The compositions of the invention therefore contribute significantly toimproving the trophism and hydration of vaginal mucosa subject todryness.

DETAILED DESCRIPTION OF THE INVENTION

The present invention discloses pharmaceutical compositions comprisinghyaluronic acid benzyl ester, wherein 50% of the carboxyl groups ofhyaluronic acid are esterified with the corresponding hydroxyl groups ofbenzyl alcohol (hyaluronic acid 50% esterified with benzyl alcohol;Hyaff11p50), for use as a topical treatment of disorders of the vaginalmucosa characterised by loss of elasticity and hydration, such asvaginal dryness and atrophic vaginitis, possibly accompanied byconcomitant inflammations or bacterial or fungal infections; saidcompositions can also be used successfully as lubricants of the genitalmucosa, even under physiological conditions.

The starting hyaluronic acid used in the present invention can derivefrom any source, such as extraction from rooster combs (EP138572), fromfermentation, as known, or from biosynthesis (from Bacillus,WO2012032154), and have an average molecular weight ranging between100,000 and 250,000 Da, in particular between 180,000 and 230,000 Da. Itshould be noted that average molecular weight here means weight-averagemolecular weight, calculated by the “intrinsic viscosity” method(Terbojevich et al., Carbohydr Res, 1986, 363-377).

The ester derivative used herein is obtained as described in EP216453,and specifically as detailed in Example 1:

Example 1

preparation of hyaluronic acid benzyl ester wherein 50% of the HAcarboxyl groups are esterified with benzyl alcohol (Hyafflp50).

10.6 g of HA tetrabutylammonium salt (weight-average molecular weight200,000 Da), corresponding to 17 milliequivalents of monomer units, issolubilised in 530 ml of dimethyl sulphoxide at 25° C., 7.8milliequivalents of benzyl bromide are added, and the resulting solutionis maintained at 30° C. for 12 hours. A solution of 62 ml of watercontaining 9 g of sodium chloride is then added, and the resultingmixture is poured slowly into 3000 ml of acetone under constantstirring. The precipitate that forms is filtered, washed three timeswith 500 ml of acetone/water 5:1, and finally dried under vacuum at 30°C. for eight hours. The precipitation stage is repeated; the precipitateis washed twice with acetone/water 5:1 and then three times with acetonealone, followed by drying under vacuum at 30° C. for 24 hours.

The end product thus obtained is hyaluronic acid wherein 50% of itscarboxyl groups are esterified with the corresponding hydroxyls ofbenzyl alcohol (Hyaff11p50). The quantitation of the ester groups isperformed according to Cundiff and Markunas, Anal Chem, 1961, 33,1028-1030.

The ester derivative thus obtained absorbs water to a lesser extent thanthe starting molecule. The replacement of 50% of the carboxyls with thearomatic groups of benzyl alcohol reduces the hydrophilicity of thestarting molecule for obvious chemical reasons and also for stericreasons; however, as described below, Hyaff11p50 unexpectedly proved tobe:

-   -   far superior to HA “as is” in hydrating the mucosa, maintaining        a long-lasting effect of freshness and well-being, though        containing a lower percentage of water;    -   able to exercise a bacteriostatic action which is useful in the        event of opportunistic infections;    -   longer-lasting, due to its lower solubility in water;    -   harmless to latex, because it has a completely aqueous base, and        can therefore be used with condoms;    -   mucoadhesive and biocompatible;

and therefore represents a definite improvement on the range of vaginalhydrating and lubricating products currently available. It can be usedfor the purposes described herein in concentrations ranging between 0.1and 1%, preferably between 0.2 and 5%, and most preferably at theconcentration of 0.2% (w/w).

Example 2

evaluation of the hydrating effect of a preparation of HA (FormulationA) and a preparation of Hyaff11p50 (Formulation B) wherein the averageMW of HA is 180,000-230,000 Da.

The formulations were prepared simply by hydrating HA powders “as is” orHyaff11p50 with an isotonic saline solution (NaCl 0.9% w/v in water) toobtain a final concentration of 0.2%.

The study was conducted ex-vivo on porcine vaginal mucosa obtained bysurgical removal and devoid of pathological diseases.

Samples of vaginal mucosa with an area of 2 cm² were placed on Petridishes and treated with 1 ml of Formulation A or Formulation B, or withan equal volume of saline solution (Control).

The samples were then moistened with 1 ml of saline solution to simulatethe vaginal environment, and stored in an incubator at 37° C. withconstant humidity. After one hour, the strips of mucosa were transferredto dry Petri dishes and, taking this as Time 0 and the maximum level ofhydration, their degree of hydration was evaluated, the control valuehaving being set at 100. The degree of hydration of the mucosa wasmeasured at pre-set times (1, 3, 6 and 24 hours, corresponding to T1,T2, T3 and T4), the samples being kept in the incubator between onemeasurement and the next. The measurement was conducted with acorneometer; the dielectric power of the water contained in the surface,which obviously varies with the water content, is measured by applying asensor to the test surface.

The results obtained, which are set out in Table 1 below, unequivocallydemonstrate that Formulation B (Hyaff11p50) has a much bettermoisturising effect than Formulation A (HA); after 24 hours the residualhydration level of the samples treated with Hyaff11p50 was more thantwice that of the samples treated with HA. This means that Formulation Byields more water to the mucosa than Formulation A.

TABLE 1 Evaluation of degree of hydration of porcine vaginal mucosasamples Product T1 T2 T3 T4 Control 41.5 28.3 13.4 2.2 Formulation A54.7 37.6 19.7 5.3 (HA) Formulation B 93.5 71.7 30.1 11.5 (Hyaff11p50)

This result is surprising, and above all entirely unexpected, as HAabsorbs far more water than the Hyaff11p50 tested.

In addition to its proven hydrating properties, the Hyaff11p50 used herealso exercises a mild but important bacteriostatic effect due to thebenzyl alcohol released by the molecules by simple hydrolysis in anaqueous environment, in the absence of specific enzymes (according toExample 3). As already stated, vaginal dryness and atrophy are oftenaccompanied by opportunistic infections; a product that keeps thisaspect under control, thereby eliminating the need for specificpharmacological treatments, would therefore be very useful. Thesetreatments are usually administered locally, and therefore have anadverse effect on an already fragile mucosa. The release of benzylalcohol from the products claimed herein can, however, inhibit theproliferation of opportunistic pathogens, as benzyl alcohol possessesbacteriostatic properties (Merck Index, 14th Edition, §1124), butwithout adversely interacting with the cells of the vaginal mucosa.

Example 3

Evaluation of release of benzyl alcohol from Hyaff11p50 in an aqueousenvironment.

Hyaff11p50 was dissolved in water and incubated in isotonic salinesolution (NaCl 0.9% w/v in water) at the concentration of 1 mg/ml at 37°for 3 days. The presence of benzyl alcohol in the incubation medium wasdetected by HPLC using a C18 column and a UV detector, and measuredafter 24, 48 and 72 hours (T1, T2 and T3 respectively). The results,calculated as the percentage of benzyl alcohol compared with the initialcontent, are set out in Table 2 below. The release of benzyl alcohol, inthe total absence of enzymes, is clearly substantial, consistent andlinear.

TABLE 2 Evaluation of release of benzyl alcohol into the medium T1 T2 T3Benzyl alcohol in 34% 57% 79% medium (% of initial content)

This means that after application to the vaginal mucosa, the benzylalcohol released can combat any bacteria and fungi present, which find afertile medium in vaginal mucosa altered by dryness.

In view of this discovery, the Applicant has devised some pharmaceuticalcompositions comprising Hyaff11p50 which are suitable for intravaginalapplication or other application to the genital apparatus, even freefrom the classic preservatives (parabens), which are often a source ofdiscomfort and stinging when applied to an inflamed mucosa, or of localallergies in particularly sensitive individuals. The Applicant hassurprisingly discovered that replacing parabens with precise glycolexcipients does not alter the hydrating and lubricating characteristicsof the product, or modify its storability.

As stated, the pharmaceutical compositions according to the inventioncan be prepared in the classic pharmaceutical forms suitable for vaginaluse, namely ovules, douches and products applied by spreading (creams orgels).

The vaginal ovules on the market are generally formulated in oilycarriers which may be unsatisfactory in many respects; for example, theovule tends to slip as the oily excipients are dissolved by body heat,thus creating significant discomfort. In the case of the invention, dueto the special characteristics of Hyaff 11p50, the ovules can beformulated with hydrophilic excipients and gelled with gelatin. In thisway, as the hyaluronic acid derivative is mucoadhesive, the ovuleadheres perfectly to the vaginal mucosa after insertion, and remains insitu for a considerable time without causing discomfort. To facilitateits application to very dry, atrophic mucous membranes, polymers thatincrease the mucoadhesion of the end product can be included in theformulation of the ovules. Some examples are derivatives of acrylicacid, cellulose (hydroxyethylcellulose, carboxymethylcellulose) or otherpolymers known.

During its residence in the vaginal channel the hydrogel-like mass ofovule gradually releases water, and exercises over time its hydrating,lubricant and refreshing action and also its antibacterial action, dueto benzyl alcohol which, as demonstrated, is released by hydrolysis intothe aqueous environment. The ovules described herein are particularlyuseful in the continuous treatment of vaginal dryness or atrophyaccompanied by minor bacterial infections or opportunistic mycosis.

On the other hand, vaginal douches are more useful as an extemporaryhydrating, refreshing, soothing and optionally cleansing treatment, tobe used alone or together with other local pharmacological treatments.

Among the pharmaceutical forms which can be applied by direct spreading,the preferred form is the gel, wherein the solution of Hyaff11p50 isgelled with acrylic acid polymers belonging to the carbomer family; ofthe various carbomers, Carbomer 974P (Carbopol®974P, Lubrizol®) willpreferably be selected, as it possesses mucoadhesive properties that areparticularly useful in this type of formulation.

Other forms suitable for vaginal administration include foams or moussesformulated with or without propellants such hydrofluorocarbons, butaneor other inert gases.

The compositions are described herein purely for demonstration purposes,the choice of the most suitable excipients being left to the skilledperson.

Example 4

Preparation of a pharmaceutical composition in the form of a gelcomprising 0.2% Hyaff11p50 (% w/w).

Hyaff11p50 0.2 Propylene glycol 10 Methyl parahydroxybenzoate 0.2 Propylparahydroxybenzoate 0.03 Carbopol ®974P 1 NaOH q.s. for pH 5.5-6.5Purified water q.s. for 100

Methyl parahydroxybenzoate and propyl parahydroxybenzoate are dissolved,under stirring, in about 98% of the total water, heated to 80° C. Thesolution is slowly cooled to 35-40° and Hyaff11p50 added, mixing forabout 30 minutes. When dissolution is complete, the propylene glycol isadded, followed by Carbopol 974P, under vacuum. NaOH is dissolved in theremaining quantity of water and added to the homogenous gel obtained inthe previous steps, adjusting the pH to values ranging between 5.5 and6.5.

Example 5

Preparation of a pharmaceutical composition in gel form comprising 0.2%Hyaff11p50 without paraben preservatives (% w/w).

Hyaff11p50 0.2 Propylene glycol 5.767 MP-Diol ® glycol 3.750 Symdiol 680.9 Carbopol ®974P 1 NaOH q.s. for pH 5.5-6.5 Purified water q.s. for100

Hyaff11p50 is added under stirring to about 98% of the total water,heated to 40° C., and mixed until dissolved. Propylene glycol andMPDiol® Glycol are then added under stirring, and mixed until dissolved.Carbopol 974P is dispersed under stirring, avoiding the formation oflumps.

NaOH is solubilised separately in the remaining quantity of water; saidsolution is then added to the preceding one under stirring, and stirringcontinues for 10 minutes, until a homogenous gel is obtained; the gel isthen cooled to ambient temperature, mixing slowly. Finally, Symdiol 68is added under stirring and mixed until the gel is homogeneous.

Example 6

Preparation of a pharmaceutical composition in the form of vaginalovules comprising Hyaff11p50 0.2% without the addition of mucoadhesivepolymers (% w/v)

Hyaff11p50 0.2 Glycerol 98% Ph. Eur. 48.35 MP-Diol ® glycol 3.750Symdiol 68 0.9 220 bloom gelatin 13.50 Lactic acid q.s. for pH 4.7-5.00Purified water q.s. for 100

88% of the purified water is heated to 70° C., and gelatin is addedslowly under stirring. Stirring continues until complete dissolution,thereby obtaining a clear, homogeneous phase, that is left under gentlestirring and heating to promote deaeration of the phase.

Glycerol, MP-Diol® Glycol and Symdiol 68 are mixed until a clear,homogeneous phase is obtained. Hyaff11p50 is added under stirring, andleft under stirring until complete dispersion. The remainder of thepurified water is added under stirring. The mixture is heated to 70-72°C., always under stirring, until a clear homogeneous phase forms.

The two phases previously obtained are combined under stirring at 70°C., and left under stirring for at least 30 minutes.

Lactic acid is added under stirring to adjust the pH to values rangingbetween 4.70 and 5.00.

The mixture is cooled to 50+/−5° C. and poured into moulds to obtainovules weighing 2200 mg each.

Example 7

Preparation of a pharmaceutical composition in the form of vaginalovules comprising Hyaff11p50 0.2% with the addition of mucoadhesivepolymer (Carbopol® 974P) (% w/w)

Hyaff11p50 0.2 Glycerol 98% Ph. Eur. 48.35 MP-Diol ® glycol 3.750Symdiol 68 0.9 220 bloom gelatin 13.50 Lactic acid q.s. for pH 4.7-5.00Carbopol ® 974P 0.1 Purified water q.s. for 100

Preparation: 88% of the purified water is heated to 70° C., and gelatinis added slowly under stirring. Stirring continues until completedissolution, thereby obtaining a clear, homogeneous phase that is leftunder gentle stirring and heating to promote deaeration of the phase.

Glycerol, MP-Diol® Glycol and Symdiol 68 are mixed until a clear,homogeneous phase is obtained. Carbopol® 974P is added under stirring,and left under stirring until complete dispersion. Hyaff11p50 is addedunder stirring, and left under stirring until complete dispersion. Theremainder of the purified water is added under stirring. The mixture isheated to 70-72° C., always under stirring, until a clear homogeneousphase forms.

The two phases previously obtained are combined under stirring at 70°C., and left under stirring for at least 30 minutes.

Lactic acid is added under stirring to adjust the pH to values rangingbetween 4.70 and 5.00.

The mixture is cooled to 50+/−5° C. and poured into moulds to obtainovules weighing 2200 mg each.

Example 8

Preparation of a pharmaceutical composition in the form of vaginalovules comprising Hyaff11p50 0.2% with the addition of mucoadhesivepolymer (Hydroxyethylcellulose)(% w/w)

Hyaff11p50 0.2 Glycerol 98% Ph. Eur. 48.35 MP-Diol ® glycol 3.750Symdiol 68 0.9 220 bloom gelatin 13.50 Lactic acid q.s. for pH 4.7-5.00Hydroxyethylcellulose (Natrosol HHX) 0.2 Purified water q.s. for 100

Preparation: see Example 7

Example 9

Preparation of a pharmaceutical composition in the form of vaginalovules comprising Hyaff11p50 0.2% with the addition of mucoadhesivepolymer (Sodium carboxymethylcellulose) (% w/w)

Hyaff11p50 0.2 Glycerol 98% Ph. Eur. 48.35 MP-Diol ® glycol 3.750Symdiol 68 0.9 220 bloom gelatin 13.50 Lactic acid q.s. for pH 4.7-5.00Sodium carboxymethylcellulose (Blanose 7MF) 0.2 Purified water q.s. for100

Preparation: see Example 8

Example 10

Preparation of a pharmaceutical composition in the form of a vaginaldouche comprising Hyaff11p50 0.2% (% w/w)

Hyaff11p50 0.2 Sodium benzoate 0.3 Potassium sorbate 0.2 Lactic acidq.s. for pH 4.5 Purified water q.s. for 100

Hyaff11p50 is added to the quantity of water required by the formula,and stirred until complete dissolution. Sodium benzoate and potassiumsorbate are then added, and stirred until complete dissolution. Finally,lactic acid is added under stirring until pH 4.5, and stirring continuesuntil a homogenous solution is obtained.

Example 11

Preparation of a pharmaceutical composition in the form of a vaginaldouche comprising Hyaff11p50 0.2% containing a detergent (% w/w)

Hyaff11p50 0.2 Sodium benzoate 0.3 Potassium sorbate 0.2 Lactic acidq.s. for pH 4.5 Cocamidopropyl betaine (detergent) 0.5 Purified waterq.s. for 100

Hyaff11p50 is added to the quantity of water required by the formula,and stirred until completely dissolved. Sodium benzoate and potassiumsorbate are then added, and stirred until complete dissolution. Finally,the detergent is added, and mixing continues until complete dissolution.Finally, lactic acid is added under stirring until pH 4.5, and stirringcontinues until homogenous.

1. Pharmaceutical compositions in form of gel, ovules, douches, foam,mousse, comprising hyaluronic acid, wherein 50% of the hyaluronic acidcarboxyl groups are esterified with benzyl alcohol, for use in the localtreatment of vaginal dryness and/or atrophic vaginitis. 2.Pharmaceutical compositions as claimed in claim 1 wherein hyaluronicacid has an average molecular weight ranging between 100,000 and 250,000Da, preferably between 180,000 and 230,000 Da.
 3. Pharmaceuticalcompositions as claimed in claim 2, wherein hyaluronic acid 50%esterified with benzyl alcohol has a concentration ranging between 0.1and 1%, preferably between 0.2 and 5%, most preferably of 0.2% w/w. 4.Pharmaceutical compositions as claimed in claim 1, for use in thetreatment of bacterial or fungal infections concomitant with vaginaldryness and/or atrophic vaginitis.
 5. Pharmaceutical compositionsaccording to claim 1 in gel form for use in the local treatment ofvaginal dryness and/or atrophic vaginitis, comprising hyaluronic acid50% esterified with benzyl alcohol at the concentration of 0.2% w/w,wherein the starting hyaluronic acid has a weight-average molecularweight ranging between 180,000 and 230,000 Da and further comprisingCarbomer 974P as gelling agent and pharmaceutically acceptableexcipients.
 6. Pharmaceutical compositions as claimed in claim 5, freefrom paraben preservatives.
 7. Pharmaceutical compositions according toclaim 1 in form of hydrophilic vaginal ovules for use in the localtreatment of vaginal dryness and/or atrophic vaginitis, comprisinghyaluronic acid 50% esterified with benzyl alcohol at the concentrationof 0.2% w/w, wherein the starting hyaluronic acid has a weight-averagemolecular weight ranging between 180,000 and 230,000 Da, optionallycontaining gelling and mucoadhesive polymers and further containingpharmaceutically acceptable excipients.
 8. Pharmaceutical compositionsaccording to claim 1 in form of vaginal douches for use in the localtreatment of vaginal dryness and/or atrophic vaginitis, comprisinghyaluronic acid 50% esterified with benzyl alcohol at the concentrationof 0.2% w/w, wherein the starting hyaluronic acid has a weight-averagemolecular weight ranging between 180,000 and 230,000 Da, and optionallycontaining detergents.
 9. Pharmaceutical compositions according to claim1 in form of foams or mousses for use in the local treatment of vaginaldryness and/or atrophic vaginitis, comprising hyaluronic acid 50%esterified with benzyl alcohol at the concentration of 0.2% w/w, whereinthe starting hyaluronic acid has a weight-average molecular weightranging between 180,000 and 230,000 Da, and optionally containingpropellants.
 10. Pharmaceutical compositions as claimed in claim 2, foruse in the treatment of bacterial or fungal infections concomitant withvaginal dryness and/or atrophic vaginitis.
 11. Pharmaceuticalcompositions as claimed in claim 3, for use in the treatment ofbacterial or fungal infections concomitant with vaginal dryness and/oratrophic vaginitis.